Feb 17, 2022 / 03:00PM GMT
Mani Foroohar - SVB Leerink LLC, Research Division - MD of Genetic Medicines & Senior Research Analyst
Good morning, next session of this year's GHC. I'm Mani Foroohar, Senior Analyst for Genetic Medicines. And at point I'm hosting Jeff Poulton, CFO of Alnylam. Jeff, how you're doing?
Jeffrey V. Poulton - Alnylam Pharmaceuticals, Inc. - CFO & Executive VP
Good. Good to be here with you today, Mani.
Questions and Answers:
Mani Foroohar - SVB Leerink LLC, Research Division - MD of Genetic Medicines & Senior Research AnalystGreat to have you. Those investing audience for the 100th time, I'm sure you guys have -- after 2 years, you guys are familiar with this as I am. The question you want to send in, of course, you can type in the interface right below my chin on the screen right now. And I'll go ahead and pass it along to Jeff.
But I'll start with one of my own. Obviously, there's a lot of squabbling about my TTR study, your TTR study and a lot of confusion about how they're going to behave.
Trustpilot
